Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics.
Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke.
lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C.
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Title: Pharmacokinetics and Pharmacodynamics of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis in the Randomised ADVANCE Study.
Pathological mechanisms in progressive multiple sclerosis.
Cognitive impairment in multiple sclerosis.
Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains.
[Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years].
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis.
Enzon presents pre-clinical data on controlled release of PEGylated interferon-beta-1b and PEGylated anti-TNF-a antibody fragment at the Controlled Release Society annual meeting
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
Discontinuation of Disease-Modifying Treatment for Multiple Sclerosis
The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis.
Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
TGN1412: From Discovery to Disaster.
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
Fourth Cooperative Meeting of Consortium of MS Centers and Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in relapsing-Remitting Multiple Sclerosis
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.

Pages